LY2599506

LY2599506 is a small molecule oral glucokinase activator that was developed for the treatment of type 2 diabetes mellitus. It acts by activating glucokinase, an enzyme that plays a key role in glucose homeostasis by facilitating phosphorylation of glucose in the liver and pancreas. By enhancing glucokinase activity, LY2599506 aims to improve glycemic control in patients with type 2 diabetes. The drug was investigated as both monotherapy and in combination with metformin or glyburide in multiple phase 2 clinical trials but development has been discontinued[1][3][5][8].

Other names

Glucokinase activator (gka) (R)-1Gka (R)-1(R)-2-(4-(Cyclopropylsulfonyl)phenyl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide